U.S. Markets closed

Aileron Therapeutics, Inc. (ALRN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2120-0.0045 (-2.08%)
At close: 04:00PM EDT
0.2111 -0.00 (-0.42%)
After hours: 07:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2165
Bid0.2111 x 1400
Ask0.2199 x 900
Day's Range0.2080 - 0.2350
52 Week Range0.1310 - 1.2700
Avg. Volume742,138
Market Cap19.202M
Beta (5Y Monthly)2.58
PE Ratio (TTM)N/A
EPS (TTM)-0.3190
Earnings DateMar 22, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
  • GlobeNewswire

    Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

    Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancerKey protocol enhancements include: Selection of 1.2 mg/kg dose of ALRN-6924 with the goal to extend duration of cell cycle arrest and, thus, chemoprotectionNew primary endpoint that is more closely aligned with regulatory preced

  • GlobeNewswire

    Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

    BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022. Management will be availabl

  • Benzinga

    Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

    Aileron Therapeutics (NASDAQ: ALRN) announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors. ALRN-6924-treated patients could stay on chemotherapy treatment longer, completing 93% of the first four cycles of carboplatin/pemetrexed administered compared to 78% on placebo. This imbalance of completed cycles may